{"entity":{"id":"nct04920617","kind":"trial","name":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymp","aka":[],"tldr":"A phase 2 trial of Pembrolizumab, Cyclophosphamide in diffuse large b-cell lymphoma, run by ImmunoVaccine Technologies, Inc. (IMV Inc.), now recruiting.","summary":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma is a phase 2 interventional study registered as NCT04920617 by ImmunoVaccine Technologies, Inc. (IMV Inc.), with 102 participants planned, started 2021-06-18 and due to reach its primary completion in 2024-10. Interventions recorded: DPX-Survivac, Pembrolizumab, CPA. Conditions listed: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04920617","url":"https://clinicaltrials.gov/study/NCT04920617"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04920617","phase":"2","setting":"A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)","sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","enrolled":102,"outcomes":[]},"route":"/trials/nct04920617/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}